ProfCatherine Greene

Associate Professor

Clinical Microbiology

  • Associate Professor
    Clinical Microbiology
  • 01 8093712 (Work)
  • RCSI, Clinical Microbiology, First Floor, ERC II, Smurfit Building, Beaumont Hospital, Dublin, 9, Ireland

RESEARCH OVERVIEW

Prof Greene's research investigates the expression and function of non-coding RNAs, particularly microRNAs (miRNAs), in lung health and disease. A central focus is cystic fibrosis (CF), a genetic disease with its highest worldwide incidence in Ireland, together with alpha-1 antitrypsin deficiency and other chronic inflammatory lung conditions including COPD and asthma. Her group study how miRNAs regulate innate immunity, inflammation and host–pathogen interactions in the airway. They also examine how this regulation is altered by infection, allergens and toxicant exposures such as cigarette smoke, and how sex- and age-related differences in non-coding RNA expression influence disease susceptibility from the newborn to the adult lung.

 

A long-term aim of the group is to translate these findings into inhaled, nucleotide-based therapeutics. To support this, she developed the MiR-CATCH methodology for identifying the RNA targets of individual miRNAs. The team also work with drug-delivery and nanomedicine collaborators on formulations suitable for delivery to the airway.

 

Prof Greene's newest research area explores the cross-kingdom antimicrobial effects of miRNAs, meaning the capacity of human miRNAs to directly affect bacterial pathogens. Using DNA-tetrahedron nanostructures to deliver miRNA mimics, she is investigating their effects on Pseudomonas aeruginosa, Staphylococcus aureus and other ESKAPE pathogens relevant to the CF lung. This work aims to establish miRNAs as a new class of antimicrobial agent at a time of rising antimicrobial resistance.

 

Her work uses human cell-based and advanced in vitro models of the airway. These reflect her view that human-relevant systems are essential for miRNA research, because miRNA target sites in 3′UTRs often differ between species.

 

Her research has been funded by Cystic Fibrosis Foundation Therapeutics, Horizon2020, the NIH, Vertex Pharmaceuticals and Science Foundation Ireland, amongst others.

GRANTS

  • FUNDED PROJECT
    Pittsburgh Summer Rotation 2026
    RCSI28 Apr 2026 - 31 Dec 2026
  • FUNDED PROJECT
    RCSI Soochow CSC Joint PhD Programme 2025 - Supplemental
    RCSI1 Sep 2025 - 31 Aug 2029
  • FUNDED PROJECT
    RCSI-Pittsburgh Joint PhD Programme 2025 Cohort
    RCSI1 Sep 2025 - 31 Aug 2030
  • FUNDED PROJECT
    In Silico and In Vitro Testing Of Novel Antibacterial Agents For Cystic Fibrosis
    Cystic Fibrosis Foundation1 Mar 2024 - 29 Aug 2025
  • FUNDED PROJECT
    RCSI-Soochow Joint PhD Programme 2023 Cohort
    RCSI29 Jun 2023 - 30 Sep 2027
  • FUNDED PROJECT
    RCSI-Soochow Joint PhD Programme 2023/4-2027/28
    RCSI1 Oct 2022 - 30 Sep 2027
  • FUNDED PROJECT
    Genetics in a loop: study of the role of circular RNAs in cystic fibrosis
    Industry10 May 2021 - 31 May 2023
  • FUNDED PROJECT
    A role for mitochondrial danger-associated molecular patterns (mtDAMPs) in AAT deficiency
    Alpha-1 Foundation (US)1 Sep 2019 - 31 Aug 2022
  • FUNDED PROJECT
    Correcting Pathogenic TGF beta Activity in the Airway
    National Institute for Health (NIH) US1 Feb 2019 - 31 Dec 2022
  • FUNDED PROJECT
    Estrogen regulation of microRNAs targeting alpha-1 antitrypsin in the female CF lung – a novel mechanism contributing to the gender gap
    Industry1 Oct 2018 - 30 Mar 2022
    People funded by this grant:
    • Vertex PL
  • FUNDED PROJECT
    'GENDER-CF' Gender-related differences in expression of microRNAs in cystic fibrosis
    EU Horizon 20201 Sep 2017 - 30 Aug 2019
    People funded by this grant:
    • Arlene G
  • FUNDED PROJECT
    Inhibition of CFTR-specific miRNAs in cystic fibrosis lung epithelial cells
    Cystic Fibrosis Foundation1 Feb 2016 - 30 Sep 2018
    People funded by this grant:
    • Ronan M,
    • Barry L,
    • Paul M
  • FUNDED PROJECT
    miRNA-mediated effects of AAT Augmentation Therapy
    Alpha-1 Foundation (US)1 Jul 2015 - 30 Jun 2016
  • FUNDED PROJECT
    MicroRNA modulation of aberrant interleukin-8 expression in cystic fibrosis bronchial epithelial cells
    National Children’s Research Centre Crumlin / NCRC1 Feb 2014 - 30 Apr 2016
  • FUNDED PROJECT
    The regulation of innate immunity in CF by X-chromosome linked miRNAs
    3U Partnership / 3U10 Sep 2013 - 9 Sep 2015
  • FUNDED PROJECT
    Capture affinity technology to isolate messenger RNA-specifc microRNAs (miR-CATCH)
    Science Foundation Ireland (SFI)1 Jan 2013 - 30 Apr 2014
  • FUNDED PROJECT
    The role of Stenotrophomonas maltophilia in cystic fibrosis lung disease.
    Health Research Board / HRB1 Jul 2012 - 30 Jun 2015
  • FUNDED PROJECT
    Autoantibodies in ZAAT deficiency
    Alpha-1 Foundation (US)1 Jul 2009 - 30 Jun 2011
  • FUNDED PROJECT
    Evaluation of apoptotic responses in human airway epithelial cells expressing Z alpha-1 antitrypsin
    Science Foundation Ireland (SFI)1 Jun 2008 - 31 Aug 2008
    People funded by this grant:
    • Matthew K
  • FUNDED PROJECT
    Defining the role of selenoprotein S in alpha-1 antitrypsin deficiency
    Alpha-1 Foundation (US)1 Jul 2007 - 30 Jun 2008